Systemic Lupus Erythematosus (SLE): Pathogenesis, Classification, and Management
Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by loss of self-tolerance, autoantibody production (especially anti-nuclear antibodies), immune complex deposition, and inflammation affecting virtually any organ.
Epidemiology
- Female:Male = 9:1 (peak 15–45 years)
- Higher prevalence and severity in Black, Hispanic, Asian populations
- Genetic (HLA-DR2/DR3, IRF5, STAT4) + environmental triggers (UV, EBV, silica, drugs, hormones)
2019 EULAR/ACR Classification Criteria (Score ≥10 with positive ANA ≥1:80)
| Domain | Criteria (Weight) |
|---|---|
| Constitutional | Fever (2) |
| Hematologic | Leukopenia (3), Thrombocytopenia (4), Autoimmune hemolysis (4) |
| Neuropsychiatric | Seizures (5), Psychosis (6), Acute confusional state (2) |
| Mucocutaneous | Non-scarring alopecia (2), Oral ulcers (2), Subacute cutaneous lupus (4), Acute cutaneous lupus (6) |
| Serosal | Pleurisy (5), Pericarditis (6) |
| Musculoskeletal | Joint involvement (6) |
| Renal | Proteinuria >0.5g/day (4), Renal biopsy Class II/V (8), Class III/IV (10) |
| Immunologic | Anti-dsDNA (6), Anti-Smith (6), Antiphospholipid Abs (2), Low complement (3), Direct Coombs (2) |
Major Organ Manifestations
- Renal (Lupus Nephritis): 40–50%; ISN/RPS classes I–VI; leading cause of morbidity/mortality
- Neuropsychiatric (NPSLE): Seizures, stroke, psychosis, cognitive dysfunction, transverse myelitis
- Cardiovascular: Accelerated atherosclerosis, pericarditis, Libman-Sacks endocarditis, vasculitis
- Pulmonary: Pleuritis, shrinking lung syndrome, PAH, alveolar hemorrhage
- Hematologic: Cytopenias, antiphospholipid syndrome (thrombosis, pregnancy loss)
- Cutaneous: Malar rash, discoid lupus, photosensitivity, vasculitis, calcinosis
Management Principles
- Hydroxychloroquine (HCQ): Foundation for all SLE patients (↓ flares, thrombosis, damage, mortality)
- Glucocorticoids: Bridge for flares; taper to lowest dose; avoid long-term >7.5 mg/day
- Immunosuppressants: Mycophenolate (renal, non-renal), Azathioprine, Methotrexate (cutaneous/articular), Cyclophosphamide (severe renal/CNS), Rituximab (refractory), Belimumab (active autoantibody+), Anifrolumab (type I IFN signature), Voclosporin (LN)
- Antiphospholipid syndrome: Anticoagulation (warfarin INR 2–3) for thrombosis
- Non-pharmacologic: Sun protection, smoking cessation, vaccination (inactivated), bone health, CVD risk reduction
Monitoring
- Disease activity: SLEDAI-2K, BILAG, PGA
- Labs q1–3 mo: CBC, Cr, urinalysis, complement (C3/C4), anti-dsDNA
- Renal: UPCR, biopsy if active sediment
- Damage accrual: SLICC/ACR Damage Index
SLE requires lifelong, multidisciplinary care—early aggressive treatment improves long-term outcomes.
Medical Billing - Related Articles
- Understanding Third-Party Liability (TPL) in Medicaid
- Medical Appointment Scheduling Abbreviations: A Comprehensive Guide
- Shadow Billing in Healthcare: Definition, Risks & Legal Consequences
- Understanding Medical Record Content Standards: The Role of The Joint Commission
- Comprehensive Patient Assessment: Components, Process & Clinical Reasoning
- Become a Certified Coding Specialist: Requirements & Career Path
- E/M Service Modifiers: A Comprehensive Guide for Accurate Coding
